• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hyperion DeFi Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    1/5/26 5:30:29 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYPD alert in real time by email
    false 0001682639 0001682639 2026-01-01 2026-01-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 1, 2026

     

     

    HYPERION DEFI, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

    Delaware   001-38365   47-1178401
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    23461 South Pointe Drive, Suite 390
    Laguna Hills, CA 92653

    (Address of Principal Executive Offices, and Zip Code)

     

    (833) 393-6684

    Registrant’s Telephone Number, Including Area Code 

     

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    (Title of each class)   (Trading
    Symbol)
      (Name of each exchange
    on which registered)
    Common stock, par value $0.0001 per share   HYPD   The Nasdaq Stock Market
    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 3.02. Unregistered Sales of Equity Securities.

     

    As previously disclosed, on June 20, 2025, Hyperion DeFi, Inc. (the “Company”) issued an aggregate of 5,435,897 shares of Series A Non-Voting Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), 5,435,897 of which remained outstanding as of September 30, 2025. On January 5, 2026, an aggregate of 100,000 shares of Series A Preferred Stock were converted into 300,000 shares of common stock, par value $0.0001 per share, of the Company (the “Conversion Shares”), for no additional consideration pursuant to the terms of the Series A Preferred Stock. The Conversion Shares were not registered under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder, or under any state securities laws.

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Chief Executive Officer Appointment

     

    On January 1, 2026, the Board of Directors (the “Board”) of the Company appointed Hyunsu Jung, who served as the Company’s Interim Chief Executive Officer since September 2025, as the Company’s permanent Chief Executive Officer, effective immediately. Mr. Jung will continue to serve as a director of the Company until the Company’s 2026 annual meeting of stockholders and thereafter until his successor has been elected and qualified or until his earlier death, resignation or removal.

     

    Mr. Jung, age 29, has served as the Company’s Interim Chief Executive Officer since September 2025, and as the Company’s Chief Investment Officer and a director since June 2025. Prior to joining the Company, from June 2021 to June 2025, Mr. Jung was a Portfolio Manager at DARMA Capital, an $1B+ asset manager registered with the CFTC and NFA. Previously, Mr. Jung was a Consultant at EY-Parthenon from October 2018 to June 2021, where he drove Finance and Digital Transformation for major enterprise M&A deals. Mr. Jung earned his B.A. from Vassar College in 2018.

     

    There is no family relationship between Mr. Jung and any other director or executive officer of the Company.

     

    In connection with his appointment as Chief Executive Officer, Mr. Jung entered into an amended and restated employment agreement with the Company (the “Employment Agreement”), pursuant to which the Company will pay Mr. Jung a base salary of $520,000. Mr. Jung will be eligible to receive equity awards as determined by the Board from time to time in its sole discretion. In addition, each calendar year, Mr. Jung will be eligible to earn a cash bonus, subject to the achievement of performance goals and conditions established by the Board or the compensation committee of the Board, in an amount up to (i) for calendar year 2026, 100% of Mr. Jung’s base salary and (ii) thereafter, a percentage of Mr. Jung’s then-current base salary as may be determined by the Board or the compensation committee in its sole discretion.

     

    Mr. Jung’s term of employment will extend until January 17, 2029, unless extended further by mutual agreement, or until earlier termination under the Employment Agreement. If Mr. Jung’s employment is terminated by the Company for cause (as defined in the Employment Agreement), by Mr. Jung without good reason (as defined in the Employment Agreement) or as a result of Mr. Jung’s disability or death, Mr. Jung is entitled to receive Accrued Obligations (as defined in the Jung Employment Agreement). If Mr. Jung’s employment is terminated by the Company other than for cause, disability or death, or by Mr. Jung for good reason, he is entitled to receive (i) Accrued Obligations, (ii) 12 months of his then-current annual base salary, less applicable withholdings and (iii) continuation of up to 12 months of group health insurance benefits.

     

     

     

     

    The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by the full text of the Employment Agreement, a copy of which is attached as Exhibit 10.1 to this Form 8-K and incorporated herein by reference.

     

    Item 7.01. Regulation FD Disclosure.

     

    On January 5, 2026, the Company issued a press release announcing the appointment of Mr. Jung as Chief Executive Officer and the appointment of Robert Rubenstein, Esq., as the Company’s General Counsel, effective as of January 12, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

     

    The information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

      

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    Number
    Description
    10.1 Amended and Restated Employment Agreement by and between Hyperion DeFi, Inc. and Hyunsu Jung, dated January 1, 2026
    99.1 Press release, dated January 5, 2026.
    104 Cover Page Interactive Data File (embedded within the inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      HYPERION DEFI, INC.
         
    Dated: January 5, 2026 By: /s/ Hyunsu Jung
        Hyunsu Jung
        Chief Executive Officer

     

     

     

    Get the next $HYPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPD

    DatePrice TargetRatingAnalyst
    12/24/2025Buy
    Chardan Capital Markets
    12/16/2025$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $HYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer

    Board Confirms Leadership Team to Execute 2026 Strategic Priorities Company Also Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that its Board of Directors has appointed Hyunsu Jung as Chief Executive Officer, effective immediately. Mr. Jung's appointment marks an important milestone in the Company's leadership evolution as it advances its strategic priorities for 2026. Mr. Jung joined Hyperion DeFi as Chief Investment Officer in June 2025, where he has focused on developing on-chain business lines, strengthening operational discipline, and expandin

    1/5/26 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Announces Receipt of Kinetiq Airdrop, Partnership with Native Markets, and Purchase of 150,000 Additional HYPE

    Receives 1,918,478.78 KNTQ in the Token Generation Event Airdrop, Plus Right to Earn Additional Yield on 28,888 HYPE Staked by the Company Partnership with Native Markets to Support Hyperliquid-Aligned USDH Stablecoin Generates Additional Yield for 300,000 HYPE Staked by the Company Announces 150,000 HYPE purchase resulting in 1,862,195 Gross HYPE Tokens Owned by the Company LAGUNA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), today announced a series of updates demonstrating its ongoing digital asset treasury growth and strong forward momentum across its DeFi strategy, including new yield opportunities, expanded e

    12/4/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Reports Third Quarter 2025 Financial Results with Record Net Income of $6.6 Million

    Management Initiates Q4'25 Adjusted Revenue(3) Guidance of 31% to 43% Q-o-Q Growth Over 13 Million HYPE Tokens Staked to Hyperion's Validator as of October 31, 2025 Ramping Business Lines Expected to Achieve Positive Operating Cash Flows in 2026 LAGUNA HILLS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today reported results for the third quarter ending September 30, 2025. "This has been an extraordinary six months for Hyperion DeFi, and we are still in the early stages of our evolution," said Hyunsu Jung

    11/13/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    SEC Filings

    View All

    SEC Form 424B3 filed by Hyperion DeFi Inc.

    424B3 - HYPERION DEFI, INC. (0001682639) (Filer)

    1/9/26 4:30:55 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    1/5/26 5:30:29 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    12/10/25 6:40:03 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $HYPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $HYPD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Hyperion Defi

    Chardan Capital Markets initiated coverage of Hyperion Defi with a rating of Buy

    12/24/25 11:52:07 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Hyperion Defi with a new price target

    Cantor Fitzgerald initiated coverage of Hyperion Defi with a rating of Overweight and set a new price target of $4.00

    12/16/25 8:52:58 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Knox David R. bought $100,340 worth of shares (27,950 units at $3.59), increasing direct ownership by 9% to 327,950 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/5/26 8:00:09 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R bought $113,091 worth of shares (30,880 units at $3.66), increasing direct ownership by 21% to 91,161 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/30/25 4:01:21 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Jung Hyunsu covered exercise/tax liability with 82,324 shares, decreasing direct ownership by 5% to 1,417,676 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/30/25 4:00:22 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Knox David R. bought $100,340 worth of shares (27,950 units at $3.59), increasing direct ownership by 9% to 327,950 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/5/26 8:00:09 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R bought $113,091 worth of shares (30,880 units at $3.66), increasing direct ownership by 21% to 91,161 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/30/25 4:01:21 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R bought $120,664 worth of shares (38,444 units at $3.14), increasing direct ownership by 33% to 75,448 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/22/25 8:15:26 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Financials

    Live finance-specific insights

    View All

    Hyperion DeFi Schedules Third Quarter 2025 Earnings Call for November 13, 2025

    LAGUNA HILLS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company dedicated to building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced that it will hold its earnings conference call and webcast for the third quarter ended September 30, 2025, on Thursday, November 13, 2025 at 5:00 p.m. Eastern Time. A press release detailing these results will be issued prior to the call on the same day. Participants may submit questions in advance of the call via email to [email protected]. A webcast of the call will be archived and available through Thursday, Novembe

    11/3/25 4:00:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

    NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ:HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi. To access the Ca

    8/8/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Leadership Updates

    Live Leadership Updates

    View All

    Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer

    Board Confirms Leadership Team to Execute 2026 Strategic Priorities Company Also Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that its Board of Directors has appointed Hyunsu Jung as Chief Executive Officer, effective immediately. Mr. Jung's appointment marks an important milestone in the Company's leadership evolution as it advances its strategic priorities for 2026. Mr. Jung joined Hyperion DeFi as Chief Investment Officer in June 2025, where he has focused on developing on-chain business lines, strengthening operational discipline, and expandin

    1/5/26 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

    PayPal's Former Head of Capital Markets and Head of Finance for Global Credit and Financial Services Joins Company Strong Advocate for Blockchain Adoption for Traditional Institutional Financial Products LAGUNA HILLS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced the appointment of David Knox, CFA, as Chief Financial Officer, effective immediately. This move is part of a broader strategic initiative to strengthen governance and accelerate the Company's decentralized finance ("DeFi") strateg

    9/29/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care